FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment

16.04.08 - 18:45 ... source : Novartis - US

... Phase II study extension shows 68-73% of patients with multiple sclerosis remained relapse-free after three years of treatment with oral FTY720 New data demonstrate 89% of patients free from active brain lesions - the injury caused by MS - three years after starting treatment MS, a devastating disease causing progressive disability, affects 2.5 million people worldwide including many young adults FTY720 regulatory filings planned before end of 2009 in US and EU East Hanover, NJ, April 15, 2008 - The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical data presented today from an ongoing Phase II study extension. Results showed that 73% of patients who began the study on FTY720 5 mg remained free from re ...» Next (HTML)